Medicare Overpaid Hospitals $26 Million for IMRT Medicare Overpaid Hospitals $26 Million for IMRT
Medicare has inadvertently overpaid hospitals nearly $26 million for outpatient intensity-modulated radiation therapy (IMRT) planning services because of improper billing.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

HHS audit finds hospitals overbill for IMRT planning
The Medicare system overpaid U.S. hospitals by nearly $26 million for...Read more on AuntMinnie.comRelated Reading: OIG questions some meaningful use payments NY mobile imaging firm hit by OIG investigation Federal probe confirms scheduling woes at Phoenix VA (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 22, 2018 Category: Radiology Source Type: news

Is radiation therapy warranted for DCIS postlumpectomy?
Researchers have found that radiation therapy after lumpectomy in women with...Read more on AuntMinnie.comRelated Reading: Microbubbles improve breast cancer radiation therapy ASTRO: Short radiation course safe for breast cancer LED device could predict skin damage from breast RT Robotic IMRT-APBI works well for breast cancer patients SABCS: Study links APBI to higher complication rates (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 10, 2018 Category: Radiology Source Type: news

Radiation Therapy Can Increase Mesothelioma Survival Time
Too many patients with malignant pleural mesothelioma are going without adjuvant radiotherapy that could extend their lives significantly, according to Dr. Bin Teh at Houston Methodist Hospital in Texas. Teh is the senior author of a recent study — the largest of its kind — that examined the role and extent of radiation therapy in the overall treatment of mesothelioma. He and his colleagues found only 3.1 percent of patients diagnosed with pleural mesothelioma underwent radiotherapy treatment in combination with aggressive surgery. “Surgery plus radiation improves overall survival,” Teh, vice chair ...
Source: Asbestos and Mesothelioma News - July 30, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Varian Expands Capabilities of Halcyon Treatment System with New Imaging Technologies
PALO ALTO, Calif., April 19, 2018 -- (Healthcare Sales & Marketing Network) -- Varian (NYSE: VAR) today announced it is incorporating new imaging technologies in the Halcyon™ 2.0 treatment system to expand its capabilities and ability to deliver high qual... Devices, Oncology Varian Medical Systems, Halcyon System, IMRT, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 19, 2018 Category: Pharmaceuticals Source Type: news

Pleurectomy and Decortication the ‘ Way to Go ’ for Mesothelioma
Dr. Pietro Bertoglio and his colleagues at the University Hospital of Pisa stopped performing the aggressive extrapleural pneumonectomy (EPP) surgery for mesothelioma more than a decade ago. They believe it’s long overdue for everyone else to do the same and instead use the less-debilitating pleurectomy/decortication (P/D) procedure. The Journal of Thoracic and Cardiovascular Surgery recently published the University Hospital of Pisa’s 10-year experience using P/D and hyperthermic intrathoracic chemotherapy (HITHOC). Two editorial commentaries from thoracic surgeons in the U.S. accompanied the study from Italy,...
Source: Asbestos and Mesothelioma News - April 16, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Proton RT for Prostate Cancer Has Reduced Toxicity, Higher Cost vs Other RT Options
Proton radiation therapy offers some reduced toxicity over IMRT in patients under the age of 65 with prostate cancer, but its cost is nearly double. (Source: CancerNetwork)
Source: CancerNetwork - March 26, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers News Prostate Cancer Source Type: news

Varian Halcyon Treatment System Receives AERB Certificate for Import & amp; Supply in India
PALO ALTO, Calif. and MUMBAI, India - Feb. 6, 2018 - Varian (NYSE: VAR) today announced the Halcyon™ cancer treatment platform has received Atomic Energy Regulatory Board (AERB) Certificate for Import and Supply in India. This registration allows Varian to now market this new system in India. Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT), and is well suited to treat a majority of cancer patients, offering...This story is related to the following:Clinical Medical Equipment (Source: Industrial Newsroom - Health, Medical and Dental Supplies)
Source: Industrial Newsroom - Health, Medical and Dental Supplies - February 7, 2018 Category: Medical Devices Source Type: news

Varian Medical acquires Mobius Medical Systems
Varian Medical (NYSE:VAR) said yesterday it bought radiation oncology quality assurance software maker Mobius Medical Systems for an undisclosed amount. The Palo Alto, Calif.-based company said the acquisition will be beneficial to its portfolio of patient treatment plan QA and machine QA technologies, and that integration of the Mobius’ technologies will enable advanced QA processes to be “seamlessly combined into treatment workflows.” Mobius’ QA software is currently in use at over 1,000 sites globally, and includes the Mobius3D dose verification and IMRT/VMAT treatment delivery system, ...
Source: Mass Device - February 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Software / IT mobiusmedicalsystems Varian Medical Systems Source Type: news

Varian Halcyon Treatment System Receives AERB Certificate for Import and Supply in India
PALO ALTO, Calif. and MUMBAI, India, Feb. 6, 2018 -- (Healthcare Sales & Marketing Network) -- Varian (NYSE: VAR) today announced the Halcyon™ cancer treatment platform has received Atomic Energy Regulatory Board (AERB) Certificate for Import and Supply i... Devices, Oncology, Regulatory Varian Medical Systems, Halcyon, IMRT, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 6, 2018 Category: Pharmaceuticals Source Type: news

No Reduced Toxicity for Proton Tx vs IMRT in NSCLC (CME/CE)
(MedPage Today) -- Study challenges assumptions about supposed superiority of proton therapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 4, 2018 Category: Hematology Source Type: news

Microbubbles improve breast cancer radiation therapy
Injecting breast cancer with oxygen-filled microbubbles makes tumors three...Read more on AuntMinnie.comRelated Reading: ASTRO: Short radiation course safe for breast cancer LED device could predict skin damage from breast RT NEJM: RT boosts heart disease risk in breast cancer patients Robotic IMRT-APBI works well for breast cancer patients SABCS: Study links APBI to higher complication rates (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 30, 2018 Category: Radiology Source Type: news

Proton Therapy Not Better Than IMRT in Lung Cancer Proton Therapy Not Better Than IMRT in Lung Cancer
In a randomized trial comparing the two modalities, proton therapy was not superior in reducing the rate of serious lung toxicityMedscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - January 18, 2018 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Varian inks Chinese cancer care deal with Ping An, wins Taiwanese nod for Halcyon
Varian Medical (NYSE:VAR) said today it signed a strategic partnership deal with Ping An Health Technology to explore expanding cancer care in China, and that it won Taiwanese approval for its Halcyon image-guided volumetric intensity modulated radiotherapy cancer treatment system. In its deal with Ping An, Palo Alto, Calif.-based Varian said both companies will explore using artificial intelligence, cloud computing and big data tech to bring high quality, cost-effective cancer care to more individuals in China. “We are pleased to be collaborating with Ping An, the leading force in the field of healthc...
Source: Mass Device - January 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Oncology Regulatory/Compliance Varian Medical Systems Source Type: news

Varian Halcyon Treatment System Receives Taiwan FDA Approval
PALO ALTO, Calif., Jan. 8, 2018 -- (Healthcare Sales & Marketing Network) -- Varian (NYSE: VAR) today announced its Halcyon™ system has received Taiwan FDA approval, which allows the company to market this new cancer treatment system in Taiwan. This appr... Devices, Oncology, Regulatory Varian Medical Systems, Halcyon, IMRT, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 8, 2018 Category: Pharmaceuticals Source Type: news

UNC Lineberger awarded $11.9M grant to study radiation treatments for prostate cancer
(UNC Lineberger Comprehensive Cancer Center) The Patient-Centered Outcomes Research Institute has awarded UNC Lineberger Comprehensive Cancer Center's Ronald C. Chen, MD, MPH, a five-year, nearly $12 million grant to fund a comparative study of intensity-modulated radiation therapy and proton beam for prostate cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 18, 2017 Category: Cancer & Oncology Source Type: news

UNC Lineberger awarded $11.9 million grant to study radiation treatments for prostate cancer
(UNC Lineberger Comprehensive Cancer Center) The Patient-Centered Outcomes Research Institute has awarded UNC Lineberger Comprehensive Cancer Center's Ronald C. Chen, MD, MPH, a five-year, nearly $12 million grant to fund a comparative study of intensity-modulated radiation therapy and proton beam for prostate cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 18, 2017 Category: International Medicine & Public Health Source Type: news

Varian Medical wins Brazilian regulatory nod for Halcyon system
Varian Medical (NYSE:VAR) said today it won Brazilian ANVISA clearance for its Halcyon image-guided volumetric intensity modulated radiotherapy cancer treatment system. The Palo Alto, Calif.-based company said its Halcyon IMRT system features improvements that make it more comfortable for patients and streamline operator’s workflow, only requiring nine steps from start to treatment, down from 30 steps in legacy machines. Varian Medical said the device is designed to handle “the majority” of cancer patients, including individuals with prostate, breast, head & neck and other forms of cancer. &...
Source: Mass Device - December 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Oncology Regulatory/Compliance Varian Medical Systems Source Type: news

Varian Halcyon Treatment System Receives ANVISA Registration in Brazil
New advanced cancer treatment system from Varian now available to cancer centers in Brazil PALO ALTO, Calif., Dec. 6, 2017 -- (Healthcare Sales & Marketing Network) -- Further expanding the global availability of its new device for cancer treatment, Va... Devices, Oncology, Regulatory Varian Medical Systems, Halcyon System, IMRT, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 6, 2017 Category: Pharmaceuticals Source Type: news

Varian Medical wins Japanese nod for Halcyon oncology radiotherapy system
Varian Medical (NYSE:VAR) said today it won Shonin approval from the Japanese Ministry of Health, Labor and Welfare for its Halcyon image-guided volumetric intensity modulated radiotherapy cancer treatment system. The Palo Alto, Calif.-based company said its Halcyon IMRT system features improvements that make it more comfortable for patients and streamline operator’s workflow, only requiring 9 steps from start to treatment, down from 30 steps in legacy machines. Varian Medical said the device is designed to handle “the majority” of cancer patients, including individuals with prostate, breast, head &a...
Source: Mass Device - November 16, 2017 Category: Medical Devices Authors: Fink Densford Tags: Oncology Regulatory/Compliance Varian Medical Systems Source Type: news

Proton therapy for prostate cancer is advantageous to imrt according to new study
(Northwestern Memorial HealthCare) Proton therapy treatment for prostate cancer is associated with higher survival rates and decreased risk of complications compared to intensity-modulated radiation therapy (IMRT) according to a new study by researchers at the Northwestern Medicine Chicago Proton Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 25, 2017 Category: International Medicine & Public Health Source Type: news

Varian launches Halcyon treatment in EU
Varian Medical (NYSE:VAR) said today it launched its Halcyon image-guided volumetric intensity modulated radiotherapy cancer treatment system in the European Union, with the 1st patient being treated in Blegium. The Palo Alto, Calif.-based company said its Halcyon IMRT system features improvements that make it more comfortable for patients and streamline operator’s workflow, only requiring 9 steps from start to treatment, down from 30 steps in legacy machines. Varian said the device is designed to handle “the majority” of cancer patients, including individuals with prostate, breast, head & neck and ot...
Source: Mass Device - October 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Oncology Varian Medical Systems Source Type: news

European Court of Appeal Rejects Varian's Attempt to Reverse Customer Purchase of Accuray TomoTherapy(R) System
SUNNYVALE, Calif., Oct. 19, 2017 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Court of Appeal of Nantes has rejected the appeal filed by Varian Medical Systems opposing the purchase of the Accur... Devices, Oncology, Litigation Accuray, Varian Medical Systems, TomoTherapy, radiotherapy, IMRT (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 19, 2017 Category: Pharmaceuticals Source Type: news

High-precision radiotherapy for prostate cancer 'shows promise'
Conclusion This study shows some promising results for targeted pelvic lymph node radiotherapy for men with advanced localised prostate cancer. However, these results can only be treated as preliminary findings for now. This was an early-stage trial that aimed to investigate whether the treatment approach is safe and to get an idea of what doses may be suitable for assessment in further trials. Although it can give an indication of effectiveness, this was not the main aim of the study. Men were not randomised to a treatment group, which means there may have been some differences in the cancers or patient characteristics of...
Source: NHS News Feed - September 26, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

ASTRO: Short radiation course safe for breast cancer
A shorter-course, higher-dose protocol for breast cancer radiation therapy...Read more on AuntMinnie.comRelated Reading: LED device could predict skin damage from breast RT Breast cancer radiation boosts heart disease risk NEJM: RT boosts heart disease risk in breast cancer patients Robotic IMRT-APBI works well for breast cancer patients ASTRO publishes guidelines for accelerated whole-breast RT (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 26, 2017 Category: Radiology Source Type: news

Varian Announces Penn Medicine Treats World's First Patient on Halcyon System
PALO ALTO, Calif., Sept. 21, 2017 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (NYSE: VAR) today announced a patient at Penn Medicine, with head & neck cancer, became the first person in the world to be treated on Varian's Halcyon™ ... Devices, Oncology Varian Medical Systems, Halcyon System, IMRT, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 21, 2017 Category: Pharmaceuticals Source Type: news

Accuray wins FDA nod for iDMS data management system
Accuray (NSDQ:ARAY)  said today it won FDA 510(k) clearance for its iDMS data management system designed for sharing data between the company’s treatment delivery platforms. The Sunnyvale, Calif.-based company said the iDMS system is designed to integrate data from its technology platforms, including the Radixact, TomoTherapy and CyberKnife systems, as well as the company’s Accuray Precision treatment planning and oncology information systems. The iDMS allows users to store and manage all patient and treatment data across multiple devices to allow for more informed, efficient radiation treatments, Acc...
Source: Mass Device - July 31, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Software / IT Accuray Inc. Source Type: news

Accuray touts study data in head-to-head between TomoTherapy and Varian ’ s RapidArc
Accuray (NSDQ:ARAY) today released data from a prospective study comparing its TomoTherapy intensity-modulated radiation therapy system with Varian Medical‘s (NYSE:VAR), RapidArc radiotherapy system, touting a higher survival rate for patients treated with its TomoTherapy system. Results from the study were published last month in the International Journal of Radiation Oncology – Biology – Physics. Accuray said that the 166-patient, multi-center study was the 1st to prospectively compare clinical outcomes across radiation platforms. In the study, 74 individuals were treated with the TomoTherapy...
Source: Mass Device - July 20, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Oncology Accuray Inc. Varian Medical Systems Source Type: news

Varian Medical wins FDA nod for Halcyon radiotherapy cancer treatment system
Varian Medical (NYSE:VAR) said today it won FDA 510(k) clearance for its Halcyon image-guided volumetric intensity modulated radiotherapy cancer treatment system. The Palo Alto, Calif.-based company said its Halcyon IMRT system features improvements that make it more comfortable for patients and streamline operator’s workflow, only requiring 9 steps from start to treatment, down from 30 steps in legacy machines. “We are proud that Halcyon has now received both 510(k) clearance and CE mark. With its human-centered and user-friendly design, Halcyon is engineered to revolutionize clinical workflow. These two ...
Source: Mass Device - July 3, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Oncology Regulatory/Compliance Varian Medical Systems Source Type: news

IUCT Oncopole Advances Cancer Care in France with the New Accuray Radixact(TM) System
The French Cancer Institute is Building its Re-irradiation and Adaptive Radiotherapy Program Using the Latest Technology Developed by Accuray SUNNYVALE, Calif., June 20, 2017 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (NASDAQ: AR... Devices, Oncology Accuray, Radixact, Delivery System, IGRT, IMRT, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 20, 2017 Category: Pharmaceuticals Source Type: news

Hitachi and MD Anderson to investigate IMPT versus IMRT for oropharyngeal cancer
Japanese-based Hitachi's subsidiary Hitachi Healthcare Americas has signed an agreement to collaborate with the University of Texas MD Anderson Cancer Centre to evaluate the intensity-modulated proton beam therapy (IMPT) in a clinical trial for oroph … (Source: Drug Development Technology)
Source: Drug Development Technology - June 8, 2017 Category: Pharmaceuticals Source Type: news

MD Anderson and Hitachi to collaborate in research for treatment of oropharyngeal cancer of the head and neck
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Hitachi Healthcare Americas Corporation, have today announced that they have entered into an agreement to collaborate on research for a unique randomized clinical trial comparing the outcomes and side-effects of intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of oropharyngeal cancer of the head and neck. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 7, 2017 Category: International Medicine & Public Health Source Type: news

New Data Reinforce Benefits of TomoTherapy(R) Platform for Mainstream Radiation Therapy Treatment Indications
Multiple Studies Presented at ESTRO 36 Demonstrate System Improves Tumor Control withReduced Toxicities SUNNYVALE, Calif., May 11, 2017 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (NASDAQ: ARAY) announced today that studies contin... Devices, Oncology Accuray, TomoTherapy, radiotherapy, IMRT (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 11, 2017 Category: Pharmaceuticals Source Type: news

New Varian Cancer Treatment Platform Draws Large Crowds at ESTRO 36 Tradeshow
Unveiled on show floor, Halcyon simplifies and enhances image-guided volumetric IMRT PALO ALTO, Calif. and VIENNA, May 8, 2017 -- (Healthcare Sales & Marketing Network) -- In front of a large crowd at the annual meeting of the European Society for Radi... Devices, Oncology Varian Medical Systems, Halcyon System, IMRT, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 8, 2017 Category: Pharmaceuticals Source Type: news

Should IMRT Be the New Standard in Esophageal Cancer?
This video discusses the use of intensity-modulated radiation therapy and whether it should be the new standard for treating patients with esophageal cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 3, 2017 Category: Cancer & Oncology Authors: Steven H. Lin, MD, PhD Tags: Videos Gastrointestinal Cancers Source Type: news

IMRT vs Proton Therapy in Esophageal Cancer
This video reviews the advantages and disadvantages of IMRT and proton therapy for the treatment of esophageal cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 3, 2017 Category: Cancer & Oncology Authors: Steven H. Lin, MD, PhD Tags: Videos Gastrointestinal Cancers Source Type: news

Select Mesothelioma Patients Still Benefit from EPP Surgery
The controversial extrapleural pneumonectomy (EPP) surgery should remain a viable option for select patients with malignant mesothelioma, despite a growing reluctance today among thoracic surgeons to recommend the procedure. When combined with intensity modulated radiation therapy (IMRT), the EPP still can benefit some patients and improve survival times significantly, according to a recent study at the Baylor Scott & White Medical Center in Temple, Texas. The retrospective look at 18 patients who underwent the EPP/IMRT combination found an average, overall survival rate of 38.2 months and a median relapse-free surviva...
Source: Asbestos and Mesothelioma News - April 17, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: extrapleural pneumonectomy intensity modulated radiation therapy mesothelioma life expectancy mesothelioma surgery mesothelioma survival rates Source Type: news

Big Difference in Early Adoption of Radiotherapy Modalities for Prostate Cancer Big Difference in Early Adoption of Radiotherapy Modalities for Prostate Cancer
The rates of early adoption of intensity-modulated radiotherapy (IMRT) and stereotactic body radiation therapy (SBRT) for older men with prostate cancer differ markedly, according to an analysis of data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - April 4, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news

IMRT associated with reduction in patient reported xerostomia
(NRG Oncology) A pooled analysis of data from NRG Oncology studies RTOG 0129 and 0522 compared intensity-modulated radiotherapy (IMRT) with three-dimensional conformal radiotherapy for patients treated for locally advanced head and neck squamous cell carcinoma. The study found that IMRT was associated with significantly reduced xerostomia and feeding tube dependency after treatment, especially in oropharyngeal cancer patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 3, 2016 Category: Cancer & Oncology Source Type: news

Intensity modulated pelvic radiation therapy reduces patient reported toxicities
(NRG Oncology) NRG Oncology investigators report better patient-reported quality of life measures for women who received intensity modulated radiation therapy (IMRT) for their pelvic radiation therapy (RT) than those who received standard RT. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 3, 2016 Category: Cancer & Oncology Source Type: news

ASCO releases updated breast RT guideline
The American Society of Clinical Oncology (ASCO) has released an updated guideline...Read more on AuntMinnie.comRelated Reading: New treatment guidelines issued for DCIS ASCO BCS: Breast MRI useful for average-risk women, too ASCO BCS research highlights benefits of mobile mammo, PET/MR ASTRO publishes guidelines for accelerated whole-breast RT IMRT reduces skin toxicity symptoms for breast cancer patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 29, 2016 Category: Radiology Source Type: news

Is IMRT for Gynecologic Cancers Less Toxic? Is IMRT for Gynecologic Cancers Less Toxic?
Pelvic IMRT reduces acute patient-reported toxicity compared to standard pelvic radiation therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 28, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Link between facility volume, radiation outcomes for head and neck cancers
The association between provider case volume and outcomes has long been suggested in cancer care. A research team has completed a review of outcomes for patients with locally advanced squamous cell head and neck cancers treated with intensity-modulated radiation therapy (IMRT) and found a distinct association between higher-volume treatment centers and improved overall survival. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 27, 2016 Category: Science Source Type: news

Accuray touts 5-year CyberKnife data in prostate cancer trial
Accuray (NSDQ:ARAY) today released 5-year data from a study of its CyberKnife stereotactic body radiotherapy device for treating prostate cancer, touting a 97% rate of freedom from cancer after treatment at 5-years. Results from the study were presented at the American Society for Therapeutic Radiology and Oncology’s annual meeting in Boston. The 21-site, 309-patient trial looked to examine whether dose-escalated SBRT can be administered across multiple institutions without grade 3+ toxicities exceeding 10%. The study followed patients for 5 years and reported toxicity, survival and relapse-free survival outcome...
Source: Mass Device - September 26, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Oncology Radiosurgery Accuray Inc. Source Type: news

Postop IMRT Reduces Bowel Obstruction in GYN Cancer (CME/CE)
(MedPage Today) -- Women with BMIs>30 less likely to develop bowel obstruction (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 23, 2016 Category: Hematology Source Type: news

Many Mesothelioma Centers Top List of Best Cancer Hospitals
The University of Texas MD Anderson Cancer Center retained its standing as the top cancer care hospital in the nation for the second consecutive year, according to U.S. News & World Report. The publication’s 2016-17 Best Hospitals for Cancer graded cancer centers from 0-100 on a variety of categories such as reputation with specialists, volume of high-risk patients, patient survival and safety, nurse intensity and advanced technologies. The purpose: Help patients make more informed health care decisions. “It’s important for patients to know that not all hospitals deliver equivalent levels of care,&rdq...
Source: Asbestos and Mesothelioma News - August 11, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: best cancer centers best cancer hospitals best hospitals for cancer best hospitals rankings best mesothelioma cancer centers md anderson cancer center mesothelioma treatment moffitt cancer center us news and world report best hospitals Source Type: news

Accuray wins FDA nod for Radixact image-guided radiotherapy
Accuray (NSDQ:ARAY) said today it won FDA 510(k) clearance for its Radixact treatment delivery platform designed for image-guided radiotherapy treatments designed for cancer patients. The company said it also won FDA clearance for its Accuray Precision treatment planning system and iDMS data management system, components of its Radixact treatment platform. “The Radixact system builds upon the unique strengths of the TomoTherapy platform. Expanded delivery capabilities enable treatment with image-guided, intensity-modulated radiation therapy to an expanded range of patients. New database features make the ring ga...
Source: Mass Device - June 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Radiosurgery Regulatory/Compliance Accuray Inc. Source Type: news

Finally, RCT Results for Proton Therapy in a CancerFinally, RCT Results for Proton Therapy in a Cancer
Results from the first randomized controlled trial of proton therapy indicate that the new technology is no better than IMRT in the treatment of lung cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 21, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Study finds adaptive IGRT for bladder preservation clinically feasible
(American Society for Radiation Oncology) A prospective study examining a trimodality treatment approach in localized bladder cancer cases using adaptive image-guided, intensity-modulated radiation therapy (IG-IMRT) found that the bladder preservation rate at three years was 83 percent. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 29, 2016 Category: Cancer & Oncology Source Type: news

New Elekta iViewDose Software Designed to Provide an Essential Safety Check for Radiation Therapy
EPID-based in vivo patient dosimetry for error detection receives US FDA 510(k) clearance and CE Mark CRAWLEY, England, March 1, 2016 -- (Healthcare Sales & Marketing Network) -- The use of highly-focused, rapid delivery techniques such as intensity mo... Devices, Oncology, Product LaunchElekta, iViewDose, dosimetry, IMRT, VMAT, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 1, 2016 Category: Pharmaceuticals Source Type: news